Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer save search
Health Equity Report Card Pilot Project to Help Close the Care Gap Highlighted on World Cancer Day
Published: 2023-02-04 (Crawled : 16:20) - prnewswire.com
SNY | News | $46.02 -2.58% -2.65% 3.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $98.55 0
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $145.2 0.25% 0.0% 6.5M
|
Health Technology
| Email alert
Add to watchlist
day care report health pilot cancer
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-02-03 (Crawled : 19:00) - biospace.com/
GILD | $84.51 3.83% 3.69% 13M
|
Health Technology
|
| O: 3.82%
H: 0.0%
C: 0.0%
trodelvy fda breast cancer
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer
Published: 2023-02-03 (Crawled : 15:00) - biospace.com/
GENE 2 d | $1.8 78.22% 43.89% 90M
|
Health Technology
|
| O: 69.85%
H: 0.0%
C: 0.0%
risk for test breast cancer
High Adoption Rate Of A New Treatment Against Cancer is likely to proliferate the Neuroendocrine Tumor Treatment CAGR: 10%|UnivDatos Market Insights
Published: 2023-02-03 (Crawled : 15:00) - prnewswire.com
NVS | $85.85 -0.29% -0.29% 3.9M
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
ABBV | News | $145.2 0.25% 0.0% 6.5M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment tumor cancer market
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Published: 2023-02-03 (Crawled : 14:20) - biospace.com/
MRNA M | $173.27 -1.75% -1.78% 2.8M
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
PSNL | $3.92 28.95% 22.45% 7.8M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
trials vaccine mrna agreement cancer
White House Recognizes FINN Partners and OffScrip Health "Heartbreak in America's Heartland" Initiative; Aligns with Biden Administration's Cancer Moonshot
Published: 2023-02-02 (Crawled : 00:00) - prnewswire.com
FNCTF | News | $9.745 -2.26%
|
Communications
| Email alert
Add to watchlist
health cancer house
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
Published: 2023-02-02 (Crawled : 13:00) - biospace.com/
VSTM A | $0.7049 0.7% 0.7% 680K
|
Health Technology
|
| O: 5.61%
H: 7.11%
C: 4.14%
cancer therapy avutometinib ras pathway defactinib lgsoc program vs-6766
Mersana Therapeutics Initiates Expansion Portion of UPGRADE-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer
Published: 2023-02-01 (Crawled : 15:00) - biospace.com/
MRSN | $7.025 1.96% 1.92% 1.3M
|
Health Technology
|
| O: 0.15%
H: 3.03%
C: 1.97%
expansion trial therapeutics cancer
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
PBYI | $4.45 1.83% 1.8% 540K
|
Health Technology
|
| O: 0.23%
H: 2.07%
C: 0.23%
nerlynx guidelines treatment for breast cancer
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
GILD | $84.51 3.83% 3.69% 13M
|
Health Technology
|
| O: 0.67%
H: 0.77%
C: -0.01%
awards breast health grants cancer
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
GH | $31.92 -1.45% -1.47% 1.9M
|
Health Services
|
| O: -0.89%
H: 3.45%
C: 1.29%
analytics health biomarker cancer
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CNTX | $0.9168 -7.39% -7.98% 450K
|
Health Technology
|
| O: 74.29%
H: 27.05%
C: -13.11%
fda breast approval cancer group elascestrant orserdu ona-xr her2-
Working With Cancer: from Davos to the Super Bowl
Published: 2023-01-31 (Crawled : 13:20) - globenewswire.com
SNY | News | $46.02 -2.58% -2.65% 3.5M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
cancer
The Caris Precision Oncology Alliance Welcomes The UCI Health Chao Family Comprehensive Cancer Center
Published: 2023-01-31 (Crawled : 12:00) - prnewswire.com
FNCTF | News | $9.745 -2.26%
|
Communications
| Email alert
Add to watchlist
health cancer
Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits
Published: 2023-01-30 (Crawled : 23:00) - prnewswire.com
JNJ | News | $164.61 -0.56% -0.01% 6.8M
|
Health Technology
|
| O: -3.75%
H: 0.0%
C: 0.0%
cancer
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
Published: 2023-01-30 (Crawled : 14:00) - biospace.com/
AZN | $63.45 0.48% 0.47% 4.8M
|
Health Technology
|
| O: 1.45%
H: 0.0%
C: 0.0%
lung trial cancer initiated
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
Published: 2023-01-30 (Crawled : 13:20) - prnewswire.com
AEMD | $0.6276 -4.91% -5.16% 630K
|
Health Technology
|
| O: 27.49%
H: 0.0%
C: 0.0%
medical contract cancer hemopurifier
Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer
Published: 2023-01-30 (Crawled : 13:20) - biospace.com/
XAIR | $7.22 7.12% 6.65% 440K
|
Technology Services
|
| O: 0.31%
H: 0.0%
C: 0.0%
cancer
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
GH | $31.92 -1.45% -1.47% 1.9M
|
Health Services
|
| O: 1.95%
H: 0.0%
C: 0.0%
guardant360 treatment fda for diagnostic breast health approval cancer esr1 mutation orserdu her2-
Stemline Therapeutics Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Published: 2023-01-30 (Crawled : 13:00) - biospace.com/
RDUS | $10.08 0.0%
|
Health Technology
| Email alert
Add to watchlist
treatment fda for breast approval therapeutics cancer orserdutm elacestrant esr1 mutation elascestrant her2-
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.